PD-L1 expression on tumor-infiltrating lymphocytes is thought to be a potential predictor for patients’ response to α-PD-1 therapy, but it is not well established for dMMR cancers because of the generally low expression [24, 25]. This evidence concerns the gene CD274 and neoplasm.